Literature DB >> 15814070

Neuromyelitis Optica.

Dean M Wingerchuk1, Brian G Weinshenker.   

Abstract

Neuromyelitis optica (Devic's syndrome) is an uncommon, idiopathic, demyelinating syndrome of the central nervous system that preferentially affects the optic nerves and spinal cord. It frequently is misdiagnosed as severe multiple sclerosis, but usually is readily distinguished from multiple sclerosis in fully developed cases because of its severity, typical magnetic resonance imaging (MRI) findings (normal brain MRI; longitudinally extensive lesions on spinal cord MRI), and cerebrospinal fluid analysis (polymorphonuclear pleocytosis and absence of oligoclonal banding). A serum autoantibody marker, NMO-IgG, is highly specific for the disorder. Most patients have relapsing disease, and natural history studies confirm early and severe disability. We treat acute myelitis and optic neuritis exacerbations with parenteral corticosteroids and use rescue plasmapheresis for severe, refractory attacks. Immunomodulatory drugs used for typical multiple sclerosis seem ineffective for relapse prevention. We recommend systemic immunosuppression, usually with azathioprine and oral corticosteroids, for most patients. Fulminant disease and breakthrough disease may respond to other forms of humoral immunotherapy such as rituximab.

Entities:  

Year:  2005        PMID: 15814070     DOI: 10.1007/s11940-005-0010-6

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.972


  27 in total

1.  The clinical course of neuromyelitis optica (Devic's syndrome).

Authors:  D M Wingerchuk; W F Hogancamp; P C O'Brien; B G Weinshenker
Journal:  Neurology       Date:  1999-09-22       Impact factor: 9.910

2.  A case of relapsing neuromyelitis optica treated with glatiramer acetate.

Authors:  Roberto Bergamaschi; Carla Uggetti; Simone Tonietti; Maria Grazia Egitto; Vittorio Cosi
Journal:  J Neurol       Date:  2003-03       Impact factor: 4.849

3.  Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine.

Authors:  R N Mandler; W Ahmed; J E Dencoff
Journal:  Neurology       Date:  1998-10       Impact factor: 9.910

4.  Neuromyelitis optica: clinical predictors of a relapsing course and survival.

Authors:  Dean M Wingerchuk; Brian G Weinshenker
Journal:  Neurology       Date:  2003-03-11       Impact factor: 9.910

5.  Plasma exchange for severe attacks of CNS demyelination: predictors of response.

Authors:  M Keegan; A A Pineda; R L McClelland; C H Darby; M Rodriguez; B G Weinshenker
Journal:  Neurology       Date:  2002-01-08       Impact factor: 9.910

Review 6.  Corticosteroids or ACTH for acute exacerbations in multiple sclerosis.

Authors:  G Filippini; F Brusaferri; W A Sibley; A Citterio; G Ciucci; R Midgard; L Candelise
Journal:  Cochrane Database Syst Rev       Date:  2000

7.  Devic's neuromyelitis optica treated with intravenous gamma globulin (IVIG).

Authors:  Jacqueline Bakker; Luanne Metz
Journal:  Can J Neurol Sci       Date:  2004-05       Impact factor: 2.104

8.  Side effects of glucocorticoid treatment. Experience of the Optic Neuritis Treatment Trial.

Authors:  G A Chrousos; J C Kattah; R W Beck; P A Cleary
Journal:  JAMA       Date:  1993-04-28       Impact factor: 56.272

9.  A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica.

Authors:  Claudia F Lucchinetti; Raul N Mandler; Dorian McGavern; Wolfgang Bruck; Gerald Gleich; Richard M Ransohoff; Corinna Trebst; Brian Weinshenker; Dean Wingerchuk; Joseph E Parisi; Hans Lassmann
Journal:  Brain       Date:  2002-07       Impact factor: 13.501

10.  Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial.

Authors:  Giuseppe Remuzzi; Mariadomenica Lesti; Eliana Gotti; Maria Ganeva; Borislav D Dimitrov; Bogdan Ene-Iordache; Giulia Gherardi; Donato Donati; Maurizio Salvadori; Silvio Sandrini; Umberto Valente; Giuseppe Segoloni; Georges Mourad; Stefano Federico; Paolo Rigotti; Vito Sparacino; Jean-Louis Bosmans; Norberto Perico; Piero Ruggenenti
Journal:  Lancet       Date:  2004 Aug 7-13       Impact factor: 79.321

View more
  21 in total

1.  Neuromyelitis optica and anti-aquaporin-4 antibodies: widening the clinical phenotype.

Authors:  G Giovannoni
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-05-18       Impact factor: 10.154

2.  Diffusion tensor imaging in the assessment of normal-appearing brain tissue damage in relapsing neuromyelitis optica.

Authors:  C S Yu; F C Lin; K C Li; T Z Jiang; C Z Zhu; W Qin; H Sun; P Chan
Journal:  AJNR Am J Neuroradiol       Date:  2006-05       Impact factor: 3.825

3.  Two subtypes of optic-spinal form of multiple sclerosis in Japan: clinical and laboratory features.

Authors:  Ichiro Nakashima; Toshiyuki Fukazawa; Kohei Ota; Chiyoko Nohara; Yoko Warabi; Takashi Ohashi; Isabelle Miyazawa; Kazuo Fujihara; Yasuto Itoyama
Journal:  J Neurol       Date:  2007-03-31       Impact factor: 4.849

4.  Detection of anti-aquaporin-4 antibodies in neuromyelitis optica: comparison of tissue-based and cell-based indirect immunofluorescence assays and ELISA.

Authors:  Yoon-Joo Kim; Seung-Won Jung; Yonggoo Kim; Yeon-Joon Park; Kyungja Han; Eun-Jee Oh
Journal:  J Clin Lab Anal       Date:  2012-05       Impact factor: 2.352

Review 5.  [Concepts of lesion development in multiple sclerosis. Current approaches and clinical-therapeutic implications ].

Authors:  C Trebst; H Wiendl; M Stangel
Journal:  Nervenarzt       Date:  2006-02       Impact factor: 1.214

Review 6.  Molecular regulation of JC virus tropism: insights into potential therapeutic targets for progressive multifocal leukoencephalopathy.

Authors:  Leslie J Marshall; Eugene O Major
Journal:  J Neuroimmune Pharmacol       Date:  2010-04-17       Impact factor: 4.147

7.  Visualization of inflammation and demyelination in 2D2 transgenic mice with rodent MRI.

Authors:  Jordan C Bell; Qingwei Liu; Yan Gan; Qiang Liu; Yaou Liu; Fu-Dong Shi; Gregory H Turner
Journal:  J Neuroimmunol       Date:  2013-09-18       Impact factor: 3.478

Review 8.  Demyelinating diseases.

Authors:  S Love
Journal:  J Clin Pathol       Date:  2006-11       Impact factor: 3.411

9.  Neuromyelitis optica immunoglobulin G in a child.

Authors:  Lynsee A Hudson; Timothy J Bernard; Brian S Tseng; Bradford R Miller; John R Corboy
Journal:  Pediatr Neurol       Date:  2006-11       Impact factor: 3.372

10.  Serum uric acid levels and neuromyelitis optica.

Authors:  Fuhua Peng; Xiufeng Zhong; Xuhui Deng; Wei Qiu; Aimin Wu; Youming Long; Xueqiang Hu; Qing Li; Ying Jiang; Yongqiang Dai
Journal:  J Neurol       Date:  2010-01-22       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.